Research Article

Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines

Yi Tan, Xing Liang Jin, Weiguo Lao, Jane Kim, Linda Xiao, and Xianqin Qu

School of Medical & Molecular Biosciences, University of Technology Sydney, Sydney, NSW 2007, Australia

Correspondence should be addressed to Xianqin Qu; xianqin.qu@uts.edu.au

Received 13 January 2015; Revised 19 February 2015; Accepted 10 March 2015

Academic Editor: Luca Miele

Copyright © 2015 Yi Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to determine whether inhibition of resistin by a synthetic antiresistin RNA (oligonucleotide) oligo ameliorates metabolic and histological abnormalities in nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in mice. The antiresistin RNA oligo and a scrambled control oligo (25 mg/kg of body weight) were i.p. injected to HFD mice. Serum metabolic parameters and hepatic enzymes were measured after 4-week treatment. The treatment significantly reduced epididymal fat and attenuated the elevated serum resistin, cholesterol, triglycerides, glucose, and insulin with an improved glucose tolerance test. Antiresistin RNA oligo also normalized serum AST and ALT levels with improved pathohistology of NAFLD. Immunoblotting and qRT-PCR revealed that decreased protein and mRNA expression of resistin in fat and liver tissues of the treated mice were associated with reduction of adipose TNF-α and IL-6 expression and secretion into circulation. mRNA and protein expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and sterol regulatory element-binding protein-1c (SREBP-1c) were also significantly decreased in the treated mice. Our results suggest that resistin may exacerbate NAFLD in metabolic syndrome through upregulating inflammatory cytokines and hepatic PEPCK and SREBP-1c. Antiresistin RNA oligo ameliorated metabolic abnormalities and histopathology of NAFLD through attenuating proinflammatory cytokines.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is emerging as an important public health problem worldwide. NAFLD is classified from the range of simple steatosis and nonalcoholic steatohepatitis (NASH) followed by fibrosis [1]. The pathology of NAFLD is characterized by excessive deposition of free fatty acids (FFAs) and triglycerides (TG) in the hepatic parenchyma [2]. NAFLD is a multifactorial disease coupled with clinical hallmarks of metabolic syndrome (MetS) including obesity, insulin resistance, dyslipidemia, and lower grade inflammation [3]. Recently, increased prevalence of NAFLD has been reported in patients with MetS and polycystic ovary syndrome (PCOS) [4, 5], suggesting that the development of NAFLD, PCOS, and MetS shares some common pathogenesis, for example, central obesity with increased adipocyte-derived cytokines and inflammatory processes [6, 7]. Increased evidence indicates that excessive abdominal fat associated with ectopic fat deposition in nonadipose tissues exacerbates inflammation and lipotoxicity through releasing various adipose-derived proteins, termed “adipokines,” into the circulation, leading to MetS and NAFLD [3, 8].

Of the identified adipose-derived adipokines, resistin seems to assert its effects on both inflammatory and insulin signalling pathways [9]. Resistin was originally discovered in the adipose tissue of mice and named for its ability to resist (interfere with) insulin action [10]. Animal studies have highlighted the ability of resistin to induce skeletal muscle and hepatic insulin resistance after both acute and chronic administration [11, 12]. Increasing evidence from clinical studies suggests that resistin is implicated in various human pathologies, including MetS, type 2 diabetes, cardiovascular disease [CVD], and obesity-related subclinical inflammation [13–16], but the role of resistin in the development of NAFLD is controversial. A few clinical studies have reported that serum resistin levels did not differ between patients with
NAFLD and without the disease [17]. However, one study has shown that excessive ectopic accumulation of fat in the liver and skeletal muscle of insulin-resistant subjects is associated with lower concentrations of serum resistin [18], while another reports increased levels of circulating resistin, but only in patients with severe liver disease [19]. These inconsistent findings indicate that the role of resistin in NAFLD should be further clarified.

The pathogenesis of NAFLD is positively correlated to overnutrition or inappropriate diet which leads to chronic elevated circulating glucose, insulin, and FFA [20]. Our previous studies have demonstrated that high-fat diet (HFD) induces metabolic syndrome accompanied by an increased accumulation of TG in the liver of rats and mice [21, 22]. Another study has shown that HFD-induced obesity in rodents is associated with the elevation of serum resistin levels and hepatic insulin resistance [23]. However, it remains to be elucidated as to whether increased resistin expression and secretion are directly implicated in NAFLD. Unlike murine resistin, resistin is mainly secreted by macrophages in humans [24], suggesting that resistin is linked to inflammation which is crucial in the pathogenesis of NAFLD [25]. The illustration of this relationship between resistin expression and elevated proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukins (ILs), will help to understand the pathogenesis of NAFLD. Furthermore, whether overexpression of resistin is involved in abnormal hepatic de novo lipogenesis remains unclear. In the present study, a synthetic RNA oligonucleotide (oligo) was designed to target the mouse resistin gene (antisestin RNA oligo) as a pharmacological tool to clarify the actual role of resistin in HFD-induced NAFLD in mice. Furthermore, whether inhibition of resistin with antisestin RNA oligo ameliorates HFD-induced metabolic syndrome and NAFLD and the possible molecular mechanisms were investigated.

2. Material and Methods

2.1. Design of RNA Oligonucleotide (Oligo) against Resistin mRNA. RNA oligo was designed to complement the start codon region of the mouse resistin gene (GenBank: AF323080.1) along the resistin mRNA based on the free energy analysis. The RNA oligo was modified with 2′-O-methyl and a 3′-butanol cap to increase the in vivo stability of RNA. The sequences of RNA oligo against resistin (antisestin oligo) and the scrambled control RNA oligo (control oligo) were 5′-GGG AAA UGA AAG GUU CUU CAU-3′ and 5′-AGA CCU CUC AUA GCA GCU GAT-3′, respectively. To validate synthetic RNA oligo could effectively block resistin expression, antisestin oligo and the control oligo were transfected into 3T3-L1 adipocytes. The efficiency of synthetic RNA oligo to block resistin expression in transfected 3T3-L1 cell was 97% determined by quantitative real-time polymerase chain reactions (qRT-PCR) assay as described previously [22].

2.2. Animals and Treatment. Male C57BL/6 mice (8 weeks of age with average body weight 20.87 g) supplied by the Animal Resources Center (Perth, Australia) were acclimatized in communal cages at 22°C, with a 12 h light, 12 h dark cycle (lights on at 0700) for 1 week and had access to a standard chow or a HFD (59% fat, 21% protein, and 20% carbohydrate by energy composition) for 10 weeks to induce insulin resistance and fatty liver disease. Body weight and food intake were measured weekly. Antiresistin RNA oligo and control oligo were freshly prepared in medical saline at the ratio of 25 mg per 5 mL. The treatment dosage and its duration were designed to ensure the maximal stable inhibition of the gene transcript of interest, which was derived from our previous study [22]. After 10-week HFD feeding, HFD mice were randomly divided into two groups (n = 10) and treated with scrambled control oligo (25 mg/kg of body weight) or antiresistin oligo (25 mg/kg of body weight) via i.p. injection every second day for 4 weeks. HFD feeding was continued during 4 weeks of treatment. 10 chow fed mice were treated with saline (5 mL/kg of body weight) i.p. injection as a normal control group to HFD fed mice with the control oligo treatment.

All experimental procedures were approved by the Joint Royal North Shore Hospital/University of Technology Sydney Animal Care and Ethics Committee and were in accordance with the National Health and Medical Research Council of Australia Guidelines on Animal Experimentation.

2.3. Intraperitoneal Glucose Tolerance Tests. At the end of 4 weeks’ treatment, all mice were subjected to the intraperitoneal glucose tolerance test (i.p.GTT) following an overnight fasting (12 hours). A glucose bolus (2 g/kg of body weight) was i.p. injected to the conscious, unrestrained mice. The blood glucose levels were determined from tail blood samples taken at 0 (prior to glucose administration), 15, 30, 60, 90, 120, and 150 min after the glucose injection using One Touch Profile glucometer. Results of i.p.GTT were expressed as integrated areas under the curves (AUC) over 150 min for glucose calculated using the Trapezoidal Rule with Graphpad prism 4 software (Graphpad Prism, CA, USA).

2.4. Blood and Tissue Sample Collection. At the end of the experiment, mice were fasted overnight (12 hours) and then deeply anaesthetized with inhalant aesthetic gas (isoflurane and nitrous oxide). Blood samples were collected from the heart and centrifuged (10 min at 1400 g) to separate the serum fraction for biochemistry assays. Liver and visceral adipose tissue were quickly excised and then stored at −80°C for later measurements.

2.5. Measurement of Metabolic Parameters. Fasting serum total cholesterols, TG, and nonesterified fatty acids (NEFAs) were analysed using enzymatic colorimetric kits obtained from Roche Diagnostics GmbH (Mannheim, Germany) and Wako Pure Chemical Industries (Osaka, Japan), respectively. Fasting serum insulin concentration was measured using ELISA kits (Linco Diagnostic Services, MO, USA). Fasting serum glucose, ALT, and AST were determined by spectrophotometric analysis using commercial kits (Dialab, Vienna, Austria). Hepatic TG was determined from liver tissue extraction using the chloroform/methanol method (2:1) described previously [16]. Whole-body insulin sensitivity
was estimated according to the homeostasis model assessment of insulin resistance (HOMA-IR) using the formula: [fasting serum glucose (mmol) times fasting serum insulin (mU/mL)]/22.5.

2.6. Liver Histological Analysis. A small portion of frozen liver tissue (n = 10) was cut and embedded with precooled optimal cutting compound (Torrance, CA, USA) for cryostat sectioning at 6 μm. The sections were mounted on microscope slides then fixed with 10% formaldehyde solution. The samples were then stained with Haematoxylin and Eosin (H&E) or Oil Red O (Sigma-Aldrich, St. Louis, MO, USA). H&E-stained slides were observed under light microscopy (Olympus, BX51 microscope, Tokyo, Japan) to investigate the architecture of liver and hepatocyte steatosis. Images were captured using an Olympus digital camera (DP70, Tokyo, Japan) with a sample size at least 80 fields per group (original magnification, ×400, 36-bit colour, 1280 × 1024 pixels). Liver steatosis was graded with semiquantitative estimation of the percentage of lipid-laden hepatocytes, according to the method previously described [18]. At least 5 different high-power fields (original magnification, ×400) were graded in a blinded way. Stained Oil Red O slides were visualized with the Olympus microscope and images were captured with digital camera (DP70, Tokyo, Japan) using Image-Pro 6.2 software (Media Cybernetics, Inc., MD, USA).

2.7. Measurement of Resistin and Proinflammatory Cytokines in Circulation. Serum resistin concentrations were measured by a commercial ELISA kit (BD Biosciences, NSW, Australia) according to the manufacturer’s instructions. Serum analysis of adiponectin was based on a commercially available mouse adiponectin ELISA kit (EZMADP-60K; Millipore, MO, USA). Serum levels of TNF-α, interleukins (IL-6 and IL-10), interferon gamma (IFNγ), and leptin were measured with a standard sandwich enzyme immunoassay method using the Bio-Plex Pro mouse cytokine assay kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. Resulting levels of TNF-α, ILs, IFNγ, leptin, and adiponectin were determined using a Bio-Plex MAGPIX array reader, which identified and quantified each specific reaction based on bead colour and fluorescent signal intensity and expressed as picogram per millilitre.

2.8. Quantitative RT-PCR Assay of mRNA Expressions in Adipose Tissue and Liver. The expression of mRNAs for resistin, the proinflammatory cytokines (TNF-α and IL-6), leptin, adiponectin in adipose tissue, TNF-α, IL-6, PEPCK, and SREBP-1c in the liver were determined by quantitative real-time polymerase chain reactions (qRT-PCR). Total RNA was extracted from 100 mg of frozen visceral fat or liver tissue of mice using TRIzol reagent (Invitrogen, Mulgrave, VIC, Australia) according to the manufacturer’s protocol. After determination of RNA concentrations by measuring the absorbance at 260/280 nm 0.5 μg RNA as template was reversely transcribed to cDNA by using QuantiTect Reverse Transcription kit (QIAGEN, Alabama, USA). cDNA was amplified using PCR assay with the mouse primer sequences listed in Table 1 (Sigma, CT, USA). β-actin was used as reference genes from Promega (Madison, WI, USA). The amplification was performed with fastStart Universal SYBR Green Master (Roche Diagnostics, Mannheim, Germany) in Mastercycler ep realplex (Eppendorf, CA, USA). The relative mRNA levels in antiresistin oligo treated mice were presented as a percentage of mRNA levels in control oligo group.

2.9. Immunoblotting Assays. Expressions of resistin protein in adipose and liver tissues as well as hepatic PEPCK and SREBP-1c were detected by immunoblot analysis. 100 mg of frozen liver or visceral fat samples was homogenized in 1 mL lysis buffer (Roche Diagnostics, Indianapolis, IN, USA). Then, the homogenates were centrifuged at 3000 × g for 10 min at 4°C. The supernatants were collected and the protein concentration of each supernatant was determined by the Bradford method. Total protein (20 μg) was separated to SDS-PAGE (4–20%) and electroblotted onto PVDF membranes. Blotted membranes were blocked with 5% skim milk in PBS with 0.05% Tween 20 and incubated with monoclonal antiresistin diluted at 1:3000 (ALEXIS Biochemicals, San Diego, CA, USA), anti-PEPCK diluted at 1:1000 (Agrisera, Vannas, Sweden), anti-SREBP-1c, and anti-β-actin diluted at 1:10000 (SC-367; Santa Cruz Biotechnology, CA, USA), respectively, and incubated overnight at 4°C; then the corresponding horseradish peroxidase-conjugated secondary antibody (1:10,000) was incubated for 2 h. Protein expressions were visualized by the ECL system (Perce, Rockford, IL) and analyzed using Quantity One 4.6.1 software of the Chemidoc XRS system (Bio-Rad Laboratories, Hercules, CA, USA).

2.10. Statistical Analyses. All values are expressed as mean± SE. Comparisons across the three groups were performed using one-way analysis of variance (ANOVA) followed by Tukey test to determine significant differences between two groups using Prism version 5 (GraphPad Inc., San Diego, CA). Coefficient of correlation was performed to evaluate whether there is any correlation between serum levels of resistin and changes of HOMA-IR and proinflammatory cytokines (TNF-α and IL-6). P value < 0.05 was considered statistically significant.

3. Results

3.1. Decreased Resistin Expression and Secretion by Antiresistin RNA Oligonucleotide. By a total of 14 weeks of HFD exposure, C57BL/6 mice increased epididymal fat mass and developed metabolic syndrome with the elevated serum AST and ALT levels when compared with chow fed mice (Table 2). In association with these metabolic changes, ELISA analyses revealed that serum resistin levels were significantly higher in HFD control mice than chow fed mice (Table 2, P < 0.01). Expression of resistin mRNA was increased by 139.6% in adipose tissue and 46.6% in the liver of HFD mice compared with chow fed mice (Figures 1(a) and 1(b), P < 0.01 and 0.01, resp.). qRT-PCR analysis also revealed that the increased expression of resistin mRNA was markedly blocked by antiresistin RNA oligo in adipose tissue and liver
Table 1: The primer sequences.

| Gene     | Nucleotide | Sequence (5' to 3') | Product size (bp) | Accession number |
|----------|------------|---------------------|-------------------|-----------------|
| Retn (resistin) | Sense      | AGA CTG CTG GCC TTC TGG GC | 194         | AF323080.1     |
|          | Antisense  | TTT CCT TTT CCT CCT TG   | 97          | NM_013693.3    |
| Tnf (TNF-α) | Sense      | ATGGCCCTCCTCTCATGATGT  | 247         | NM_031168.1    |
|          | Antisense  | TGCTGCTACGAGTGGTGACAAA | 126         | NM_01044       |
| Il6 (IL-6) | Sense      | GAT GCT ACC AAA CTG GAT ATA ATC GTTG CTCT CCA CTC TTG TG | 185         | NM_011480.3    |
|          | Antisense  | GGTCCTTAGCCACTCCTTCTGTG | 126         | NM_01044       |
| Pck1 (PEPCK) | Sense      | TGCGGATCATGACTCGGATG  | 126         | NM_011044      |
|          | Antisense  | AGGCCCAGTTGTTGACCAAAA | 185         | NM_011480.3    |
| Adipoq (adiponectin) | Sense     | GGAACCTGTGCAAGTGATGTC  | 171         | NM_009605.4    |
|          | Antisense  | CCGCTCATTGCCAATGGTGAT  | 171         | NM_009605.4    |
| Lep (leptin) | Sense      | CACCAGGATCAATGACATTTCACA | 71          | NM_008493.3    |
|          | Antisense  | TGAAGTCCAAGCCAGTGACC | 71          | NM_008493.3    |
| Actb (β-actin) | Sense      | GTACA CTGGCATCGTGATGGACT | 323         | NM_007393      |
|          | Antisense  | CCGCTCATTGCCAATGGTGAT  | 323         | NM_007393      |

Table 2: Effect of antiresistin RNA oligo on body weight, metabolic parameters, and hepatic enzymes.

| Paradigm parameter | Chow | HF-Con-oligo | HF-Res-oligo |
|--------------------|------|--------------|--------------|
| After treatment Bwt (g) | 28.5 ± 0.9 | 32.8 ± 1.2a | 32.1 ± 1.7d |
| Epididymal fat (g/100 g Bwt) | 1.58 ± 0.05 | 3.3 ± 0.12b | 2.62 ± 0.32ad |
| Serum glucose (mM) | 6.70 ± 0.75 | 9.59 ± 0.72a | 7.22 ± 0.30 |
| Serum insulin (pg/mL) | 528 ± 150 | 689 ± 121a | 503 ± 164d |
| HOMA-IR | 22.8 ± 1.9 | 50.1 ± 6.4a | 27.5 ± 6.2d |
| Serum cholesterol (mM) | 3.90 ± 0.09 | 6.87 ± 0.21b | 4.95 ± 0.37d |
| Serum triglyceride (mM) | 0.63 ± 0.01 | 0.98 ± 0.02b | 0.79 ± 0.04a |
| Serum NEFA (mM) | 0.78 ± 0.16 | 1.03 ± 0.08a | 0.83 ± 0.03d |
| Serum ALT (U/L) | 29.9 ± 0.6 | 89.6 ± 9.5b | 52.1 ± 10.3d |
| Serum AST (U/L) | 32.4 ± 7.9 | 199.8 ± 21.7c | 65.8 ± 11.7f |
| Serum resistin (pg/mL) | 513 ± 36 | 668 ± 35b | 472 ± 19f |

Mice were fed standard chow and high-fat diet for 10 weeks and then with 4-week i.p injection (3 times/week) of saline (Chow, 5mL/kg of body weight), scrambled control oligo (HF-Con-oligo 25mg/kg of body weight), or antiresistin RNA oligo (HF-Res-oligo, 25mg/kg of body weight). Metabolic parameters are represented as mean ± SEM (n = 10 each group) after 4 weeks’ treatment. Bwt: body weight; HOMA-IR: homeostatic model assessment-insulin resistance; TG: triglycerides; NEFAs: nonesterified fatty acids; AST: aspartate aminotransferase; ALT: alanine aminotransferase. aP < 0.05, bP < 0.01, and cP < 0.001 versus HF-Con-oligo group.

3.2. Effects of Antiresistin RNA Oligo on Body Weight, Metabolic Parameters, and Hepatic Enzymes. Table 2 shows that the body weight of HFD fed mice was significantly higher than Chow fed mice (P < 0.05). The body weight gain was slightly lower in antiresistin treated group than the control oligo group but there was no statistical significance. However, the weight of epididymal fat mass was significantly lower in antiresistin oligo treated mice when compared with the Con-oligo group (P < 0.05). HFD feeding significantly increased fasting serum glucose level (P < 0.05 HFD versus Chow fed mice) associated with 30.7% elevation of serum insulin levels (P < 0.05), indicating insulin resistance. Antiresistin oligo treatment significantly decreased fasting serum glucose (Table 2, Res-oligo versus Con-oligo group, P < 0.05) associated with improved insulin resistance, evidenced by a reduction of fasting serum insulin levels (P < 0.01) and reduced HOMA-IR values (Table 2, P < 0.05). Antiresistin
oligo also significantly reduced the elevated serum levels of cholesterol, TG, and NEFAs levels by 27.9%, 20.1%, and 19.4%, respectively, (all $P < 0.05$) when compared with the HF-Con oligo group. Serum hepatic enzyme (AST and ALT) levels in HFD fed mice were increased by 3.0- and 6.2-fold, respectively, when compared with chow fed mice (Table 2, both 0.001). Antiresistin oligo treatment significantly attenuated the elevated AST and ALT values ($P < 0.05$ and $P < 0.001$, resp.) when compared with control oligo treated mice (Table 2).

3.3. Effect of Antiresistin RNA Oligo on i.p.GTT. Impaired glucose tolerance was induced by HFD feeding, showing significantly increased AUC of glucose profile values by 32.7% over the entire i.p.GTT (Figures 2(a) and 2(b), AUG 1757 ± 61 versus 2610 ± 179 mM·min, $P < 0.01$). Blood glucose disposal was significantly faster in antiresistin RNA oligo treated mice, evidenced by 29.7% reduction of AUC values compared with the HF-control oligo group (Figure 2, $P < 0.05$). The results of i.p.GTT together with HOMA-IR (Table 2) indicate that antiresistin RNA oligo improved whole-body insulin resistance in HFD mice. Reduction of serum levels of resistin was positively correlated to the enhanced insulin sensitivity in antiresistin RNA oligo treated mice (Figure 2(c), $P < 0.001$).

3.4. Effect of Antiresistin RNA Oligo on Lipid Deposition in the Liver and Hepatic Steatosis. The photomicrographs of the HE stain showed that the majority of the hepatocytes of HFD mice were distended by fat accumulation in comparison to the chow group (Figure 3(a)). Analysis of blindly scored HE-stained sections showed a statistically significant increase in lipid-laden hepatocytes in the liver tissue of control oligo treated mice (Figure 3(c), $P < 0.05$ versus chow fed mice). The treatment with antiresistin oligo decreased the grade of hepatic steatosis compared with control oligo group (Figures 3(a) and 3(c)), indicating that antiresistin RNA oligo greatly prevented lipid infiltrations and hepatic steatosis. Oil
Figure 2: Effects of antiresistin RNA oligo on intraperitoneal i.p. glucose tolerance test. (a) Blood glucose response to i.p. glucose injection, (b) area under the curves (AUC) of glucose profile values in chow fed mice and HFD fed mice treated with a control oligo or antiresistin RNA oligo, and (c) the correlations between serum levels of resistin and whole-body insulin sensitivity index (HOMA-IR). Data are mean ± SE (n = 10 each group). b P < 0.01 versus chow fed mice; e P < 0.05 versus HF-Con-oligo group.

Red O staining exhibited many lipid droplets in the liver sections of HFD control mice (Figure 3(b)), whereas few or no lipid droplets were seen in the liver sections from the chow and antiresistin RNA oligo treated HFD mice (Figure 3(b)). Consistent with histological appearance, the hepatic TG levels were significantly higher in HFD fed mice than those in chow fed group (Figure 3(d), 11.3 ± 0.9 versus 7.4 ± 0.9 μM/g, P < 0.05). This increase was significantly prevented by antiresistin RNA oligo treatment (Figure 3(d), P < 0.05 versus Con-oligo group). Together with normalized serum AST and ALT levels (Table 2), these findings indicate that inhibitions of resistin expression and secretion with RNA oligo can improve HFD-induced pathological changes in NAFLD.

3.5. Effects of Antiresistin RNA Oligo on Serum Proinflammatory Cytokines, Leptin, and Adiponectin. Figure 4 shows significantly increased serum TNF-α, IL-6, and leptin associated with 55.6% reduction of adiponectin in HFD control mice as compared with the chow group (P < 0.05), whereas antiresistin oligo treatment markedly decreased the elevation of TNF-α and IL-6 (Figures 4(a) and 4(b), both P < 0.05). There were neither significant alterations of circulating IL-10 and IFNγ levels by HFD feeding nor changes of serum leptin level by antiresistin oligo treatment (Figures 4(c), 4(d), and 4(e)). Interestingly, the levels of serum adiponectin were the lowest in the HF-control group and increased by 36.3% in antiresistin oligo treated group (Figure 4(f), P < 0.05 versus HF-control).

According to the fact that resistin is mainly secreted by macrophages in humans we hypothesised that resistin implicates NAFLD through upregulating secretion of proinflammatory cytokines from adipose tissue. The illustration of the relationship between circulating levels of resistin and proinflammatory cytokines will help to understand underlying mechanism by which antiresistin RNA oligo improved NAFLD pathology. Figures 4(g) and 4(h) showed reduced serum resistin was correlatively associated with decreased serum levels of TNF-α and IL-6 (both P < 0.001).

3.6. Effects of Antiresistin RNA Oligo on mRNA Expressions of Proinflammatory Cytokines, PEPCK and SREBP-1c. Figure 5(a) shows that mRNA expressions of TNF-α, IL-6, and leptin in adipose tissue were significantly higher in the HFD control mice as compared with chow fed mice. These results were consistent with the measurements in the circulation, indicating that HFD feeding induced TNF-α, IL-6, and leptin gene expression and secretion. Inhibition of resistin with RNA oligo was associated with reduced mRNA expressions of TNF-α, IL-6, and increased adiponectin (Figure 5(a), all P < 0.05) but antiresistin oligo did not affect leptin gene expression (Figure 5(a)). In the liver, TNF-α, IL-6, and mRNA also significantly increased by HFD feeding and decreased by antiresistin oligo treatment (Figure 5(b)). To clarify whether resistin implicates hepatic glucose production and hepatic fatty acid synthesis, the gene expressions involved in hepatic gluconeogenesis and lipogenesis pathways were detected. mRNA expression of PEPCK and SREBP-1c was significantly increased in HFD control group as compared with chow fed mice. The mRNA of PEPCK in antiresistin oligo treated mice was significantly lower than HFD-control group (Figure 5(b), P < 0.05). SREBP-1c mRNA was reduced by 68.5% in antiresistin oligo treated mice compared with the HFD control (P < 0.01).

3.7. Effects of Antiresistin RNA Oligo on Expressions of PEPCK and SREBP-1c in the Liver. To clarify whether inhibition of resistin mRNA alters protein expression of PEPCK and
SREBP-1c both molecules in the liver were detected by immunoblotting. When compared with chow group, chronic HFD feeding led to 50% increase in PEPCK protein content in the liver (Figure 6(a), P < 0.01). Antiresistin oligo treatment significantly decreased PEPCK protein expression compared to control oligo treatment (Figure 6(a), P < 0.05). HFD feeding also led to 75% increase in SREBP-1c protein expression in the liver (Figure 6(b), P < 0.01). Antiresistin oligo treatment reversed overexpression of SREBP-1c protein compared to control oligo treatment (Figure 6(b), P < 0.01).

4. Discussion

Resistin has been recognised as an adipocytokine positively correlated with insulin resistance and type 2 diabetes and is predictive of cardiovascular disease [15, 16]. However, the role of resistin in obesity associated with fatty liver disease remains controversial [17–19]. In the present study, we aimed to (1) identify whether the development of NAFLD induced by HFD feeding in mice is associated with overexpression of resistin mRNA and protein in adipose tissue and the liver; (2) observe whether inhibition of resistin expression with synthetic RNA oligo attenuates metabolic and histological abnormalities in NAFLD; and (3) clarify whether and which inflammatory cytokines and signalling molecules are involved in resistin-mediated hepatic insulin resistance and NAFLD.

This study discovered that, after a total of 14 weeks of HFD exposure, C57BL/6 mice developed abdominal obesity associated with hyperlipidaemia, hyperinsulinemia, and impaired
GTT. Resistin mRNA and protein expressions were markedly increased in white adipose tissue of HFD control mice, which led to elevated circulating resistin levels. The previous study showed that elevated plasma resistin is associated with hepatic insulin resistance induced by 3 weeks’ HFD feeding in mice and that treatment with antisense resistin suppressed hepatic resistin [23]. However, that overexpression of resistin links to NAFLD has not been examined [23]. Our study showed that, on HFD exposure for 14 weeks, C57BL/6 mice developed moderate hepatic steatosis with elevated serum AST and ALT, indicating pathological changes of NAFLD in HFD mice. Interestingly, resistin mRNA and protein expressions were also significantly higher in liver tissue of HFD mice, suggesting that resistin is involved in HFD-induced NAFLD. Because resistin in rodents is primarily expressed by adipocytes the induced expression of resistin protein and mRNA in the liver is possibly secondary to hepatic fat accumulation in HFD mice. Furthermore, our
Figure 5: Effects of antiresistin RNA oligo on mRNA expression. (a) TNF-α, IL-6, leptin, and adiponectin mRNA expression in adipose tissue; (b) hepatic mRNA expression of TNF-α, IL-6, PEPCK, and SREBP-1c in chow fed mice and HFD fed mice treated with a control oligo or antiresistin oligo. Data are mean ± SE (n = 10). *P < 0.05 and **P < 0.01 versus chow fed mice; dP < 0.05 versus HFD-Con-oligo mice.
study found that reduction of resistin with RNA oligo treatment ameliorated hyperinsulinemia and improved impaired GTT. Antiresistin oligo treatment also improved hyperlipidaemia and hepatic TG accumulation and normalized hepatic enzymes and the histological spectrum of hepatic steatosis in HFD mice. The NEFA levels in antiresistin treated mice were significantly reduced, consequently diminishing the influx of free FFAs to the liver, and thus attenuated FFAs-induced lipotoxicity. FFAs have direct hepatotoxicity through the induction of an endoplasmic reticulum stress response and subsequent activation of the mitochondrial pathway of cell death [26]. Lipotoxicity is a key pathogenic process in NAFLD, and it correlates with progressive inflammation and fibrosis [27].

Several lines of studies have shown a very strong and consistent association between resistin and inflammatory diseases in humans [8, 24, 25]. The mechanisms of NAFLD are closely linked to adipose dysfunction which increases secretion of proinflammatory cytokines, including TNF-α, IL-6, transforming growth factor-β, and retinol binding protein-4 [8, 22, 27–29]. TNF-α has been implicated in insulin resistance and liver fibrosis as well as advanced stages of NAFLD in humans [28]. IL-6, as a proinflammatory cytokine, has been proposed as a potential mediator leading to NAFLD [29]. In this study, we observed that elevated circulating resistin was associated with increased serum TNF-α, IL-6, and leptin; on the other hand, adiponectin was decreased in HFD fed mice. The elevated levels of serum resistin, TNF-α, IL-6, and hepatic enzymes suggest that resistin may contribute to NAFLD, at least in part, through upregulating systemic and hepatic inflammation.

The key finding of this study is that treatment with synthetic RNA oligo significantly reduced adipose mass and attenuated overexpression of resistin along with normalized serum TNF-α and IL-6 and enhanced adiponectin. Consequently, glucose intolerance and histopathological changes in the liver were improved by antiresistin RNA oligo treatment. Thus, it is highly likely that the events in the liver are due to the primary effects of the intervention on the adipose tissue events. A previous study showed that loss of resistin prevented hepatic steatosis is related to leptin deficiency [30]. In our study, reduced resistin expression and secession by RNA oligo neither significantly affected serum leptin levels nor altered leptin mRNA expression in adipose tissue. This study provided evidence to support the notion that resistin plays an important role in the pathogenesis of NAFLD but its effect is independent of the leptin pathway. Lowering resistin by RNA oligo with reduction of circulating TNF-α and IL-6 might provide a new insight into managing inflammation-mediated diseases, such as NAFLD, type 2 diabetes, and cardiovascular disease.

Our previous study showed that HFD-induced NAFLD in rats is associated with decreased insulin activation of glycogen synthase and increased gluconeogenesis [31], which, in turn, exacerbates hyperglycemia. In this study, antiresistin oligo treatment attenuated the elevated serum glucose, possibly through regulating hepatic gluconeogenesis and decreasing glucose production. Liver gluconeogenesis is driven by the availability of gluconeogenic substrates and the activity of PEPCK and glucose 6-phosphatase [32]. To understand whether antiresistin oligo also influences enzymes involved in gluconeogenesis, the expression of hepatic PEPCK was detected by qRT-PCR and Western blotting in liver tissues. We observed that the elevated serum level of resistin was associated with the expression of PEPCK in the liver of HFD mice. Furthermore, we found that inhibition of resistin with RNA oligo decreased PEPCK expression. Antiresistin RNA oligo treatment significantly reduced serum glucose level associated with downregulation of PEPCK expression, suggesting that inhibition of resistin may be a potential therapy for hyperglycemia through downregulation of hepatic PEPCK.

Figure 6: Effects of antiresistin RNA oligo on PEPCK and SREBP1c expression in the liver. Immunoblots and quantitative analysis of PEPCK (a) and SREBP-1c (b) protein in liver tissue of chow fed mice and HFD fed mice treated with a control oligo or antiresistin oligo. Data are mean ± SE (𝑛=10). 

\( b P < 0.01 \) versus chow fed mice; 

\( d P < 0.05 \) and 

\( e P < 0.01 \) versus HFD-Con-oligo mice.
The hallmark of NAFLD is the presence of ectopic fat in the hepatocytes. The underlying mechanism of this pathological fat deposition, mainly triglycerides [33], is involved in an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via FFA oxidation or triglyceride-rich lipoprotein secretion) which eventually triggers lipid peroxidative stress and hepatic injury [34]. In this study, HFD feeding caused hyperlipidemia associated with markedly elevated levels of serum AST and ALT, indicating hepatocytes injury and hepatic overproduction of lipids. The rate of hepatic lipogenesis is controlled by sterol regulatory element-binding proteins (SREBPs) which enhance transcription of genes encoding enzymes of triglycerides and fatty acid biosynthesis and uptake [35]. SREBPs have three subtypes, SREBP-1a, SREBP-1c, and SREBP-2. Among them, SREBP-1c is most highly expressed in brown fat, followed by the liver [36]. Previous study showed that SREBP-1c as a key transcription factor regulating the gene expression of key enzymes implicated in lipogenesis in the liver is experimentally connected to NAFLD [37]. To understand the mechanism underlying reduced hepatic lipid accumulation by antiresistin RNA oligo we measured SREBP-1c mRNA and protein expression in liver tissues of HFD mice with or without antiresistin RNA oligo treatment. We showed that elevated serum resistin was positively related to SREBP-1c mRNA and protein expression in the liver of HFD mice. Inhibition of resistin with RNA oligo was associated with markedly decreased SREBP-1c expression, which is likely to reduce hepatic triglyceride biosynthesis (de novo lipogenesis) and outflux. Conversely, previous study showed that increase in cellular neutral lipid content induced by human resistin is mediated through the induction of the cellular SREBP-1 and SREBP-2 lipogenic pathways [38]. A recent study reported that SREBP-1 expression and transcriptional activity were not affected in antiresistin siRNA 3T3-L1 cells [39]. The different findings between the current in vivo study and previous in vitro study by Ikeda et al. may be due to SREBP-1c gene selectively expressed in the liver and relevantly low level of SREBP-1 expression in 3T3-L1 cells. Together with increased lipid content associated overexpression of resistin and SREBP-1c in HFD mice, this study demonstrated that resistin promotes hepatic lipogenesis and hepatic steatosis through, at least in part, upregulating SREBP-1c. Inhibition of resistin may indirectly control hepatic lipogenesis pathway.

5. Conclusions

This study demonstrated that (1) downregulation of resistin expression in adipose tissue and the liver with decreased circulating resistin levels normalized HFD-induced hyperlipidemia and hyperglycemia; (2) reduction of elevated serum resistin levels by antiresistin RNA oligo was associated with a reduction of circulating TNF-α and IL-6 but with no influence on serum leptin, indicating that resistin-mediated hepatic steatosis occurs through upregulation of inflammation independent of the leptin pathway; (3) antiresistin oligo may be capable of regulating gluconeogenesis and lipogenesis in the liver through downregulation of hepatic PEPCK and SREBP-1c expression. The effect of antiresistin RNA oligo in mice may not be directly translated to clinical study because the murine resistin protein has only 59% of similarity to human one [40, 41]. Our findings that inhibition of resistin with antisense RNA oligo ameliorated metabolic and histological abnormalities in animal model of NAFLD highlighted the role of resistin in pathogenesis of NAFLD. This study also demonstrated a correlative relationship between resistin and TNF-α as well as IL-6, suggesting the proinflammatory cytokines as the molecular link between murine resistin- and human resistin-mediated NAFLD.

Abbreviations

ALT: Alanine aminotransferase
AST: Aspartate aminotransferase
AUC: Areas under the curve
HFD: High-fat diet
ILs: Interleukins
IPGTT: Intraperitoneal glucose tolerance test
Mets: Metabolic syndrome
NAFLD: Nonalcoholic fatty liver disease
NEFA: Nonesterified fatty acids
PEPCK: Phosphoenolpyruvate carboxykinase
RNA oligo: RNA oligonucleotide
SREBP-1c: Sterol regulatory element-binding protein-1c
TG: Triglycerides
TNF-α: Tumor necrosis factor-α.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Xiaqin Qu and Xing Liang Jin designed research; Yi Tan contributed to animal experiments and with Weiguo Lao, Xing Liang Jin, and Jane Kim, Linda Xiao performed laboratory assays; Xianqin Qu wrote the paper.

Acknowledgments

The authors would like to thank the scientists at Oligo Etc., Inc., USA, for their kindly synthesized antiresistin RNA oligonucleotide and scramble RNA oligonucleotide for this study. This work was supported by University of Technology Sydney Industry Partner (Oligo Etc., Inc., USA) scheme grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

References

[1] P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002.
[2] R. Anty and M. Lemoine, “Liver fibrogenesis and metabolic factors,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, supplement 1, pp. s10–s20, 2011.
M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. C.M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin,” Digestive and Liver Disease, vol. 46, no. 3, pp. 288–289, 2014.

H. Rahmanpour, L. Jamal, S. N. Mousavinasab, A. Esmailzadeh, and K. Azarkhish, “Association between polycystic ovarian syndrome, overweight, and metabolic syndrome in adolescents,” Journal of Pediatric and Adolescent Gynecology, vol. 25, no. 3, pp. 208–212, 2012.

E. Vassilatou, “Nonalcoholic fatty liver disease and polycystic ovary syndrome,” World Journal of Gastroenterology, vol. 20, no. 26, pp. 8351–8363, 2014.

P. Dietrich and C. Hellerbrand, “Non-alcoholic fatty liver disease, obesity and the metabolic syndrome,” Best Practice & Research Clinical Gastroenterology, vol. 28, no. 4, pp. 637–653, 2014.

M. H. Jarra, A. Baranova, R. Collantes et al., “Adipokines and cytokines in non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 5, pp. 412–421, 2008.

P. G. McTernan, C. M. Kusminski, and S. Kumar, “Resistin,” Current Opinion in Lipidology, vol. 17, no. 2, pp. 170–175, 2006.

C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001.

R. R. Banerjee, S. M. Rangwala, J. S. Shapiro et al., “Regulation of fasted blood glucose by resistin,” Science, vol. 303, no. 5661, pp. 1195–1198, 2004.

S. M. Rangwala, A. S. Rich, B. Rhoades et al., “Abnormal glucose homeostasis due to chronic hyperresistinemia,” Diabetes, vol. 53, no. 8, pp. 1937–1941, 2004.

M. S. Jamaluddin, S. M. Weakley, Q. Yao, and C. Chen, “Resistin: functional roles and therapeutic considerations for cardiovascular disease,” British Journal of Pharmacology, vol. 165, no. 3, pp. 622–632, 2012.

E. Malo, O. Ukkola, M. Jokela et al., “Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish health 2000 survey,” Metabolic Syndrome and Related Disorders, vol. 9, no. 3, pp. 203–210, 2011.

H.-L. Lu, H.-W. Wang, Y. Wen, M.-X. Zhang, and H.-H. Lin, “Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes,” World Journal of Gastroenterology, vol. 12, no. 11, pp. 1747–1751, 2006.

M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader, “Resistin is an inflammatory marker of atherosclerosis in humans,” Circulation, vol. 111, no. 7, pp. 932–939, 2005.

C. C. Zou, L. Liang, F. Hong, J. F. Fu, and Z. Y. Zhao, “Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children,” Endocrine Journal, vol. 52, no. 5, pp. 519–524, 2005.

G. Perseghin, G. Lattuada, F. de Cobelli, G. Ntali, and A. Esposito, “Serum resistin and hepatic fat content in non-diabetic individuals,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 5122–5125, 2006.

C. Pagano, G. Soardo, C. Pilon et al., “Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 1081–1086, 2006.

F. Nascimbeni, L. di Tommaso, M. Piccoli, A. Lonardo, and E. Vassilatou, “Nonalcoholic fatty liver disease and polycystic ovary syndrome in non-alcoholic steatohepatitis: chance tetrad or association by necessity?” Digestive and Liver Disease, vol. 46, no. 3, pp. 288–289, 2014.

G. Perseghin, G. Lattuada, F. de Cobelli, G. Ntali, and A. Esposito, “Serum resistin and hepatic fat content in non-diabetic individuals,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 12, pp. 5122–5125, 2006.

C. Pagano, G. Soardo, C. Pilon et al., “Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3, pp. 1081–1086, 2006.

I. C. Gaemers and A. K. Groen, “New insights in the pathogenesis of non-alcoholic fatty liver disease,” Current Opinion in Lipidology, vol. 17, no. 3, pp. 268–273, 2006.

Y. Tan, W. Lao, L. Xiao et al., “Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome with Chinese herbal extracts in high-fat diet fed rats,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 306738, 10 pages, 2013.

Y. Tan, L.-Q. Sun, M. A. Kamal, X. Wang, J. P. Seale, and X. Qu, “Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1811, no. 12, pp. 1045–1053, 2011.

E. D. Muse, S. Obici, S. Bhanot et al., “Role of resistin in diet-induced hepatic insulin resistance,” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 232–239, 2004.

L. Patel, A. C. Buckels, I. J. Kinghorn et al., “Resistin is expressed in human macrophages and directly regulated by PPARα activators,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472–476, 2003.

S. S. Pang and Y. Y. Le, “Role of resistin in inflammation and inflammation-related diseases,” Cellular & Molecular Immunology, vol. 3, no. 1, pp. 29–34, 2006.

C. M. Kusminski, S. Shetty, L. Orci, R. H. Unger, and P. E. Scherer, “Diabetes and apoptosis: lipotoxicity,” Apoptosis, vol. 14, no. 12, pp. 1484–1495, 2009.

S. H. Ibrahim, R. Kohli, and G. J. Gores, “Mechanisms of lipotoxicity in NAFLD and clinical implications,” Journal of Pediatric Gastroenterology and Nutrition, vol. 53, no. 2, pp. 131–140, 2011.

C. R. A. Lesmana, I. Hasan, U. Budhihusodo et al., “Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis,” Journal of Digestive Diseases, vol. 10, no. 3, pp. 201–206, 2009.

F. Hong, S. Radaeva, H. N. Pan, Z. Tian, R. Veech, and B. Gao, “Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease,” Hepatology, vol. 40, no. 4, pp. 933–941, 2004.

Y. Qi, Z. Nie, Y.-S. Lee et al., “Loss of resistin improves glucose homeostasis in leptin deficiency,” Diabetes, vol. 55, no. 11, pp. 3083–3090, 2006.

V. T. Samuel, Z.-X. Liu, X. Qu et al., “Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease,” The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32345–32353, 2004.

A. Barthel and D. Schmoll, “Novel concepts in insulin regulation of hepatic gluconeogenesis,” American Journal of Physiology - Endocrinology and Metabolism, vol. 285, no. 4, pp. E685–E692, 2003.

G. Musso, R. Gambino, and M. Cassader, “Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD),” Progress in Lipid Research, vol. 48, no. 1, pp. 1–26, 2009.

P. Ferré and F. Foufelle, “Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c,” Diabetes, Obesity and Metabolism, vol. 12, no. 2, pp. 83–92, 2010.
[35] I. Shimomura, Y. Bashmakov, and J. D. Horton, “Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus,” The Journal of Biological Chemistry, vol. 274, no. 42, pp. 30028–30032, 1999.

[36] H.-Y. Seo, M.-K. Kim, Y.-A. Jung et al., “Clusterin decreases hepatic SREBP-1c expression and lipid accumulation,” Endocrinology, vol. 154, no. 5, pp. 1722–1730, 2013.

[37] I. Shimomura, M. Matsuda, R. E. Hammer, Y. Bashmakov, M. S. Brown, and J. L. Goldstein, “Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice,” Molecular Cell, vol. 6, no. 1, pp. 77–86, 2000.

[38] J. Costandi, M. Melone, A. Zhao, and S. Rashid, “Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling,” Circulation Research, vol. 108, no. 6, pp. 727–742, 2011.

[39] Y. Ikeda, H. Tsuchiya, S. Hama, K. Kajimoto, and K. Kogure, “Resistin affects lipid metabolism during adipocyte maturation of 3T3-L1 cells,” FEBS Journal, vol. 280, no. 22, pp. 5884–5895, 2013.

[40] S. Ghosh, A. K. Singh, B. Aruna, S. Mukhopadhyay, and N. Z. Ehtesham, “The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications,” Gene, vol. 305, no. 1, pp. 27–34, 2003.

[41] M. Filková, M. Haluzík, S. Gay, and L. Šenolt, “The role of resistin as a regulator of inflammation: implications for various human pathologies,” Clinical Immunology, vol. 133, no. 2, pp. 157–170, 2009.